{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:04Z","timestamp":1791979084200,"version":"4.4.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40121-023-00868-0","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:04:04Z","timestamp":1695715444000},"page":"2295-2305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category"],"prefix":"10.1007","volume":"12","author":[{"given":"Ming M.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Adema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C.","family":"Mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey N.","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J.","family":"Tande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-3264","authenticated-orcid":false,"given":"Christina G.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"868_CR1","doi-asserted-by":"crossref","unstructured":"Satlin MJ, Nicolau DP, Humphries RM, et al. Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2020:70(6):1240\u20136.","DOI":"10.1093\/cid\/ciz845"},{"key":"868_CR2","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 29th ed. CLSI supplement M100. Wayne: Clinical and Laboratory Standards Institute; 2019."},{"issue":"6","key":"868_CR3","doi-asserted-by":"publisher","first-page":"e00203","DOI":"10.1128\/JCM.00203-19","volume":"57","author":"RM Humphries","year":"2019","unstructured":"Humphries RM, Abbott AN, Hindler JA. Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol. 2019;57(6):e00203-e219.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"868_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1086\/659152","volume":"32","author":"M Kamboj","year":"2011","unstructured":"Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol. 2011;32(4):391\u20134.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"868_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jmii.2017.08.025","volume":"51","author":"JJ Ye","year":"2018","unstructured":"Ye JJ, Shie SS, Cheng CW, et al. Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia. J Microbiol Immunol Infect. 2018;51(6):705\u201316.","journal-title":"J Microbiol Immunol Infect"},{"issue":"8","key":"868_CR6","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/cid\/cix024","volume":"64","author":"YC Chuang","year":"2017","unstructured":"Chuang YC, Lin HY, Chen PY, et al. Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia. Clin Infect Dis. 2017;64(8):1026\u201334.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"868_CR7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/jac\/dky072","volume":"73","author":"F Foolad","year":"2018","unstructured":"Foolad F, Taylor BD, Shelburne SA, Arias CA, Aitken SL. Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: a review. J Antimicrob Chemother. 2018;73(9):2277\u201383.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"868_CR8","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/jac\/dkac164","volume":"77","author":"YC Chuang","year":"2022","unstructured":"Chuang YC, Lin HY, Yang JL, et al. Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin. J Antimicrob Chemother. 2022;77(8):2278\u201387.","journal-title":"J Antimicrob Chemother"},{"key":"868_CR9","doi-asserted-by":"crossref","unstructured":"Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among veterans affairs patients. Clin Infect Dis. 2017:64(5):605\u201313.","DOI":"10.1093\/cid\/ciw815"},{"issue":"4","key":"868_CR10","doi-asserted-by":"publisher","first-page":"ofac065","DOI":"10.1093\/ofid\/ofac065","volume":"9","author":"KA West","year":"2022","unstructured":"West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia. Open Forum Infect Dis. 2022;9(4):ofac065.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"868_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/11597460-000000000-00000","volume":"35","author":"PW Kim","year":"2012","unstructured":"Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012;35(6):447\u201357.","journal-title":"Drug Saf"},{"key":"868_CR12","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 5. National Institutes of Health, National Cancer Institute; 2017."},{"issue":"1","key":"868_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"868_CR14","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1093\/cid\/ciy287","volume":"67","author":"RK Dare","year":"2018","unstructured":"Dare RK, Tewell C, Harris B, et al. Effect of statin coadministration on the risk of daptomycin-associated myopathy. Clin Infect Dis. 2018;67(9):1356\u201363.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"868_CR15","doi-asserted-by":"publisher","first-page":"ofab568","DOI":"10.1093\/ofid\/ofab568","volume":"8","author":"M Samura","year":"2021","unstructured":"Samura M, Hirose N, Kurata T, et al. Identification of risk factors for daptomycin-associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability. Open Forum Infect Dis. 2021;8(12):ofab568.","journal-title":"Open Forum Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00868-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00868-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00868-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:26:48Z","timestamp":1697567208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00868-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["868"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00868-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ming M. Zhang, Ryan W. Stevens, Jennifer L. Adema, Kristin C. Mara, Audrey N. Schuetz, Aaron J. Tande, and Christina G. Rivera declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. Ming M. Zhang is currently affiliated with Northwestern Memorial Hospital but was affiliated with Mayo Clinic \u2013 Rochester at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was deemed to be exempt by the Mayo Clinic Institutional Review Board (approval number Mod20-011769-02) and was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Informed consent was waived because of the retrospective nature of the study. The analysis used anonymized clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}